Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach.
With GH001, we have completed two Phase 1 clinical trials (GH001-HV-101 and GH001-HV-103) in healthy volunteers and a Phase 1/2 clinical trial (GH001-TRD-102) in patients with treatment-resistant depression (TRD) as well as Phase 2 open-label trials in patients with bipolar II disorder and postpartum depression.
Ongoing trials with GH001 include a Phase 2b clinical trial in patients with TRD.
For the most recent clinical trial results with GH001 in TRD, see the latest News Release
GH002 is our mebufotenin product candidate formulated for administration via a proprietary intravenous administration approach. In Q4 2023 we successfully completed a Phase 1 clinical trial of GH002 (GH002-HV-105) in 64 healthy volunteers.
Mebufotenin for inhalation administration
Trial Name: GH001-TRD-201; Status: Ongoing; ClinicalTrials.gov ID: NCT05800860
Trial Name: GH001-PPD-203; Status: Ongoing; ClinicalTrials.gov ID: NCT05804708
Swipe to view the full table
Mebufotenin for i.v. administration
Trial Name: GH002-HV-105; Status: Completed; ClinicalTrials.gov ID: NCT05753956
Swipe to view the full table